title: Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.
abstract: OBJECTIVE
  To investigate the therapeutic effect of the hepatic arterial administration of sorafenib in rabbit VX-2 hepatocellular carcinoma (HCC) model.
  
  
  METHODS
  Rabbit VX-2 HCC models were established via implanting VX-2 tumors into the livers, and randomly divided into four groups, respectively treated with (1) The hepatic arterial administration of iodized oil alone (TACE-i), (2) The hepatic arterial administration of iodized oil and pharmorubicin (TACE-ip), (3) The hepatic arterial administration of iodized and cis-DDP (TACE-ic), (4) The hepatic arterial administration of iodized and sorafenib (TACE-is). The growth rate and intrahepatic metastasis of implanted VX-2 tumor in each rabbit were measured. Microvessel density (MVD) in the adjacent tissues of implanted VX-2 tumor were estimated by detecting the expression of CD34 and VEGF level in tumor adjacent tissues were also examined by Immunohistochemistry.
  
  
  RESULTS
  Compared with other groups, TACE-is treatment group presented a better effect on inhibiting tumor growth rate and intrahepatic metastasis in rabbit VX-2 HCC model. The angiogenesis (assessed by MVD) in the adjacent tissues were suppressed more dramatically in TACE-is treated group. Moreover, TACE-is treatment did not significantly increase the levels of alanine transaminase and creatinine compared to the group with TACE-i treatment.
  
  
  CONCLUSIONS
  The hepatic arterial administration of sorafenib and iodized oil (TACE-is) effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX-2 HCC model without obvious hepatic and renal toxicity. One of the related mechanisms may be due to the inhibition of angiogenesis in the adjacent tissues. Our data indicated that TACE-is may be a secure and effective treatment for HCC.
authors.affiliation: Department of Interventional Radiology, Chinese PLA General Hospital Beijing 100853, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Interventional Radiology, Chinese PLA General Hospital Beijing 100853, China.
authors.forename: Feng-Yong
authors.initials: FY
authors.lastname: Liu
authors.affiliation: Department of Interventional Radiology, Chinese PLA General Hospital Beijing 100853, China.
authors.forename: Jin-Xin
authors.initials: JX
authors.lastname: Fu
authors.affiliation: Department of Interventional Radiology, Chinese PLA General Hospital Beijing 100853, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Duan
authors.affiliation: Department of Interventional Radiology, Chinese PLA General Hospital Beijing 100853, China.
authors.forename: Qing-Sheng
authors.initials: QS
authors.lastname: Fan
authors.affiliation: Department of Interventional Radiology, Chinese PLA General Hospital Beijing 100853, China.
authors.forename: Mao-Qiang
authors.initials: MQ
authors.lastname: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D007269:Injections, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage / Q000627:therapeutic use*; D008099:Liver / Q000098:blood supply* / Q000187:drug effects / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D007459:Iodized Oil; D000077157:Sorafenib
keywords: Hepatocellular carcinoma; MVD; TACE; VEGF; sorafenib